Selected Grants
A First-in-Human Phase 1b, Single-Blind, Placebo-controlled Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate Safety and Pharmacokinetics of GS-0415 in People With HIV-1 who are Virologically Suppressed on Antiretroviral
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2026 - 2036AI-driven Multimodal Model for PrEP Candidacy Assessment in Women (AiM-PrEP)
ResearchCo Investigator · Awarded by National Institutes of Health · 2026 - 2031A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2024 - 2030ISLEND-1 A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir (B/F/TAF)
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2024 - 2030Interdisciplinary Research Training Program in AIDS
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2010 - 2030Ryan White HIV/AIDS Program Part D Coordinated HIV Services and Access to Research for Women, Infants, Children and Youth in Central North Carolina
Public ServicePhysician · Awarded by Health Resources and Services Administration · 2010 - 2030A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naive Persons with HIV-1 (INNOVATE Study)
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline LLC · 2026 - 2029NOTRE: optimizing long-acting pre-exposure prophylaxis and medications for opioid use disorder interventions in carceral settings
ResearchCo Investigator · Awarded by National Institute on Drug Abuse · 2024 - 2029Regional AIDS Education and Training Centers
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Vanderbilt University Medical Center · 2015 - 2029Development and pilot implementation of a community-partnered, digital health-enabled outreach strategy to enhance PrEP linkage and retention for people who use substances
ResearchCo-Principal Investigator · Awarded by National Institute on Drug Abuse · 2026 - 2028RFA # A-379 Program Area Three Housing Opportunities for Persons with AIDS- Region Six
Public ServicePrincipal Investigator · Awarded by NC Dept of Health and Human Services · 2016 - 2027RFA# A-379- Housing Opportunities for Persons with AIDS- Region Seven
Public ServicePrincipal Investigator · Awarded by NC Department of Health and Human Services · 2015 - 2027Ryan White HIV/AIDS Program Part D Support Services
Public ServicePrincipal Investigator · Awarded by New Hanover Regional Medical Center · 2015 - 2027Integrated Targeted Testing Services (ITTS)
Public ServicePrincipal Investigator · Awarded by NC DHHS · 2016 - 2027Enhancing PrEP Uptake and Retention Among Latinx Transgender Women and Gay, Bisexual, and Other Men who have Sex with Men in the South Using Long-Acting Injectable PrEP
Clinical TrialCo-Principal Investigator · Awarded by Gilead Sciences, Inc. · 2025 - 2027UNC IAP Study
Clinical TrialSite PI · Awarded by University of North Carolina - Chapel Hill · 2026 - 2027NCDHHS RFA # A-379 -Region 7 Ryan White Part B Network of Care
Public ServicePrincipal Investigator · Awarded by NC Dept of Health and Human Services · 2025 - 2027Ryan White HIV Adult ID Services-Part B
Public ServicePrincipal Investigator · Awarded by Wake County Human Services · 2022 - 2027Evidence2Practice (E2P): A PrEP Capacity Building and HIV Workforce Development Initiative
Inst. Training Prgm or CMECo Investigator · Awarded by ViiV Healthcare · 2025 - 2027A Phase 2 Randomized, Open-label Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With the Capsid Inhibitor Lenacapavir as Long-Acting Treatment Dosed Every 6 Months in Virologica
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2023 - 2026Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1- The CM Study
Clinical TrialPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2023 - 2025Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1- The CM Study
ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2022 - 2025MATEC Text Messaging Intervention to Improve Antiretroviral Adherence among HIV-Positive Youth (TXTXT)
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by University of Illinois at Chicago · 2023 - 2025MACS/WIHS Combined Cohort Study (MWCCS Clinic Screener)
ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2023 - 2025NCDHHS RFA # A-379 -Region 7 Ryan White Part B Network of Care
Public ServicePrincipal Investigator · Awarded by NC Dept of Health and Human Services · 2016 - 2025IGHID 11417 - PHI 05 - The Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine Initiated During Acute HIV Infection: Impact on the Latent HIV Reservoir and Long-Term Immunologic Effect
Clinical TrialPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2015 - 2024Effects of I'm Fully Empowered4PrEP Intervention on HIV Prep Uptake by Southern African American Women
Clinical TrialPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2022 - 2024A Multi-level, Salon-Based Intervention to Promote Awareness, Accurate Knowledge and Uptake of PrEP Among Black Women Living in the United States South
ResearchCo Investigator · Awarded by Gilead Sciences, Inc. · 2020 - 2024Ph 2a multicenter, randomized, open label, two part adaptive design study to evaluate the antiviral effect safety and tolerability of GSK 3810109A, an HIV-1 specific broadly neutralizing human monoclonal antibody in antiretroviral naive HIV-1 adults
Clinical TrialPrincipal Investigator · Awarded by ViiV Healthcare · 2021 - 2023The development and validation of a scale to measure Treatment Regimen Fatigue among older adults living with HIV
ResearchCo Investigator · Awarded by National Institutes of Health · 2022 - 2023Modeling the effects of chronic marijuana use on neuroinflammation and HIV-related neuronal injury
ResearchCo Investigator · Awarded by National Institutes of Health · 2020 - 2023Phase IIIb study evaluating switching to long acting Cabo+long acting Rilp Q2months in HIV adults who are virally suppressed
Clinical TrialPrincipal Investigator · Awarded by ViiV Healthcare · 2021 - 2023STYLE 2.0
Public ServiceAdvisor · Awarded by Health Resources and Service Administration · 2018 - 2023GS - US - 380-5310
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2019 - 2022Ryan White HIV Adult ID Services, Year 4
Public ServicePrincipal Investigator · Awarded by Wake County Human Services · 2018 - 2022A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clnical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1
Clinical TrialPrincipal Investigator · Awarded by ViiV Healthcare · 2015 - 2021Randomized study to evaluate Tocilizumab in patients with severe COVID-19 pneumonia (WA42380)
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2020 - 2021BIKTARVY- GS-US-380-4580
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2018 - 2020Bringing PrEP to Campus: Examining Strategies for PrEP Delivery to Historically Black College and Universities (HBCU)
ResearchCo Investigator · Awarded by National Institutes of Health · 2005 - 2020"A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Hemodialysis [GS-US-292-1825]
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2016 - 2020GS-US-380-4030
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2017 - 2019Integrated Targeted Testing Services (ITTS)
Public ServicePrincipal Investigator · Awarded by Durham County Health Department · 2018 - 2019Substance Abuse Center (SAC)
Public ServicePrincipal Investigator · Awarded by Wake County Human Services · 2016 - 2019Gilead - GS-380-1878
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2016 - 2019GS-US-380-1961
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2016 - 2019HIV Early Intervention Testing
Public ServicePrincipal Investigator · Awarded by Alliance Behavioral Healthcare · 2016 - 2018GS-US-380-1489
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2016 - 2018Gilead - GS - US - 380-1844
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2016 - 2017Phase 3 Open-Label Stdy to Eval Switch Opt Stable Antiretro Reg Cont Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2013 - 2017GS-US-380-1490
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2016 - 2017Phase 3, 2-part Study to Eval Efficacy of Tenofovir Alafenamide vs Placebo Added to Failing Regimen Followed by Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Positive Antiretroviral Treatment-Experienced Adults
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2013 - 2016HIV and Asthma in the Post- ART Era
ResearchCo Investigator · Awarded by National Institutes of Health · 2014 - 2016Ryan White Region 6 Network of Care
Public ServicePrincipal Investigator · Awarded by Wake County Human Services · 2015 - 2016Substance Abuse Center-5 (SAC-5): Counseling, Testing and Referral in Durham, Caswell, Orange, Person and Wake
Public ServicePrincipal Investigator · Awarded by NC DHHS · 2015 - 2016The Youth Education and Prevention (Y.E.P.) Network (Ready-To-Respond Initiative)
Public ServicePrincipal Investigator · Awarded by Department of Health and Human Services · 2010 - 2016Bundled Testing and Patient navigation
Public ServicePrincipal Investigator · Awarded by Cape Fear Memorial Foundation · 2014 - 2015HIV Early Intervention Testing
Public ServicePrincipal Investigator · Awarded by Alliance Behavioral Healthcare · 2014 - 2015Substance Abuse Center-5 (SAC-5): Counseling, Testing and Referral in Durham, Caswell, Orange, Person and Wake
Public ServicePrincipal Investigator · Awarded by NC DHHS · 2014 - 2015Housing Opportunities for Persons with AIDS
Public ServicePrincipal Investigator · Awarded by NC Dept of Health and Human Services · 2014 - 2015Housing Opportunities for Persons with AIDS
Public ServicePrincipal Investigator · Awarded by NC Department of Health and Human Services · 2014 - 2015Ryan White Part B Region 7 Network of Care
Public ServicePrincipal Investigator · Awarded by NC Department of Health and Human Services · 2014 - 2015Healthy Relationships: Region Seven Prevention for Positives
Public ServicePrincipal Investigator · Awarded by NC DHHS · 2014 - 2014Substance Abuse Center-5 (SAC-5): Counseling, Testing and Referral in Durham, Caswell, Orange, Person and Wake
Public ServicePrincipal Investigator · Awarded by NC DHHS · 2013 - 2014FirstSigns-Integration of Prevention in Primary Care Through Training, Testing, and Education
Public ServiceMedical Director · Awarded by Substance Abuse and Mental Health Services Administration · 2005 - 2011External Relationships
- Viiv (GlaxoSmithKline)
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.